Gland Pharma Limited EBITDA Margin for the year ending March 31, 2025: 22.59%

Gland Pharma Limited EBITDA Margin is 22.59% for the year ending March 31, 2025, a -15.21% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Gland Pharma Limited EBITDA Margin for the year ending March 31, 2024 was 26.65%, a -20.10% change year over year.
  • Gland Pharma Limited EBITDA Margin for the year ending March 31, 2023 was 33.35%, a -15.69% change year over year.
  • Gland Pharma Limited EBITDA Margin for the year ending March 31, 2022 was 39.55%, a -5.76% change year over year.
  • Gland Pharma Limited EBITDA Margin for the year ending March 31, 2021 was 41.97%, a -1.39% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin